Quoin Pharmaceuticals Reports Positive Data Related to Two of Its Netherton Syndrome Clinical Studies
The clinical stage, specialty pharmaceutical company focused on rare and orphan diseases Quoin Pharmaceuticals (Nasdaq: QNRX), has announced positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies.
The company has reported the first subject dosed twice daily with QRX003 in its open label study has shown positive clinical data at the mid-point of testing. Additionally, Quoin reported significant improvement in skin appearance after only 12 days of dosing with QRX003 from its pediatric study.
Quoin CEO, Dr. Michael Myers, stated, “While cautioning that this is interim clinical data from a very limited number of subjects, we are very pleased to announce these early results from two of our ongoing Netherton Syndrome clinical studies. Having previously announced positive data for subjects dosed once-daily for 12 weeks in our ongoing open-label study, we are excited to share initial data for the first subject dosed twice-daily to reach six weeks of dosing in this study. Although clear improvements were observed across all four measured endpoints, the reduction in MIASI from 18 at baseline to just 4 after six weeks of dosing with QRX003 is particularly noteworthy. Similarly, the reduction in pruritus severity from 7, out of a maximum of 11, to 4 after six weeks of dosing with QRX003 is also promising.
“Furthermore, it is very encouraging to observe such a clear improvement in skin condition in the investigator pediatric study, after just 12 days of being treated with QRX003. The change from an IGA classification of severe prior to dosing to mild-moderate after such a short period of time is highly encouraging as we seek to recruit additional pediatric subjects in Spain and the United Kingdom. We remain steadfast in our commitment to develop a safe and effective treatment for the Netherton Syndrome community.”
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Disclaimer
This communication was produced by Prism MarketView. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PRISM” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PRISM see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…
